Cancer Links

• NeuVax Trial Information
• Cancer publication
• The American Breast Cancer Foundation
• American Cancer Society
• American Society of Clinical Oncology
• Avon Walk for Breast Cancer
• BreastCancer.org
• The Breast Cancer Research Foundation
• Bright Pink
• Cancer.net
• Cancer Care, Inc.
• Cancer Support Community
• Keep A Breast
• Lance Armstrong Foundation
• National Breast Cancer Coalition
• National Breast Cancer Foundation
• National Cancer Institute
• National Coalition for Cancer Survivorship
• National Foundation for Cancer Research
• National Patient Advocate Foundation
• Sisters Network
• Susan G. Komen Breast Cancer Foundation
• The Wellness Community
• Y-Me National Breast Cancer Organization
• Young Survival Coalition

NeuVax (nelipepimut-S) Publications

• Benavides L. C. Review of HER2 Breast Cancer Vaccines. Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines Expert Rev. Vaccines 10(2), 201-210 (2011)
• Mittendorf, E.A. et. al. Review of NIH Breast Cancer Vaccine Trials. Mittendorf, E.A. et. al. Breast Cancer Vaccines: On-going National Cancer Institute-registered clinical trials Expert Rev. Vaccines 10(6) 755-774 2011
• A.K. Sears, et. al. ASCO 2011, Sequential administration of trastuzumab and a CD8 T-cell-eliciting HER2/neu peptide vaccine in patients with breast cancer compared to trastuzumab alone. J Clin Oncol 29: 2011 (suppl; abstr 564)
• Clifton et. al.ASCO BREAST 2010, Abstract #254: Clinical efficacy of the E75 peptide vaccine: Cumulative findings of phase I/II trials. Podium presentation.
  Cancer. 2010 Sep 15. [Epub ahead of print]
• Holmes JP, et. al.Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
• Benavides LC, et. al. The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.Clin Cancer Res. 2009 Apr 15;15(8):2895-904. Epub 2009 Apr 7.
• Holmes JP, et. al. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer. 2008 Oct 1;113(7):1666-75.
• Gates JD, et. al. The E75 HER2/neu peptide vaccine Cancer Immunol Immunother. 2008 Jun 7. [Epub ahead of print]
• Gates JD, et. al. Monitoring Circulating Tumor Cells in Cancer Vaccine Trials Hum Vaccin. 2008 Apr 16;4(5). [Epub ahead of print]
• Amin A, et. al. Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02 Cancer Immunol Immunother. 2008 Apr 8. [Epub ahead of print]
• Peoples GE, et. al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02 Clin Cancer Res. 2008 Feb 1;14(3):797-803.
• Stojadinovic A, et. al. Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study Ann Surg Oncol. 2007 Dec;14(12):3359-68. Epub 2007 Sep 29.
• Assessment of circulating tumor cell (CTC) patterns among disease-free breast cancer patients vaccinated with a preventive HER2/neu E75-peptide vaccine Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 3059
• Clinical and immunologic effects of a HER2/neu (E75) peptide vaccine booster in previously vaccinated breast cancer patients. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 3014
• Mittendorf, Peoples, et. al. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer Ann Surg Oncol 13:1085-98, 2006
• Mittendorf, Peoples, et. al. Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer Surgery. 2006 Mar;139(3):407-18
• Hueman, Peoples, et. al. Phase I Clinical Trial of a HER-2/neu Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients Clin Cancer Research 11:7470-7479, 2005
• Peoples, et. al. Clinical Trial Results of a HER2/neu (E75) Vaccine to Prevent Recurrence in High-Risk Breast Cancer Patients
  JCO 23: 1-10, 2005
• Woll, Ponniah, Peoples, et. al. Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients J Clin Immunol 24: 449, 2004
• Woll, Peoples, et. al. Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer Intl. J Oncology 25: 1769-1780, 2004
• Castilleja, Murray, Ioannides, et. al. Induction of Tumor-Reactive CTL by C-Side Chain Variants of the CTL Epitope HER-2/neu Protooncogene (369-377) Selected by Molecular Modeling of the Peptide: HLA-A2 Complex J Immunology 169:3545-3554, 2002
• Murray, Peoples, Ioannides, et. al. Toxicity, Immunogenicity, and Induction of E75-specific Tumor-lytic CTLs by HER-2 Peptide E75 (369 –377) Combined with Granulocyte Macrophage Colony-stimulating Factor in HLA-A2+ Patients with Metastatic Breast and Ovarian Cancer.Clin Cancer Research 8: 3407-3418, 2002
• Anderson, Peoples, Murray, Ioannides, et. al. Peptide Priming of Cytolytic Activity to HER-2 Epitope 369–377 in Healthy Individuals. Clinical Cancer Research 6: 4192-4200, 2000

FBP Publications

• Clifton GT, Sears AK, Clive KS, Holmes JP, Mittendorf EA, Ioannides CG, Ponniah S and Peoples GE. Folate Receptor α, A Storied Past and Promising Future in Immunotherapy.Human Vaccines 2011; 7:2, 1-8.
• Chianese-Bullock KA, Irvin Jr WP, Petroni GR, Murphy C, Smolkin M, Olson WC,Coleman E, Boerner SA, Nail CJ, Neese PY, Yuan A, Hogan KT, Slingluff Jr CL. A multiple vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J Immunother 2008; 31:420-430.
• Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, Fisher C, Shriver CD, Ioannides CG, and Ponniah S. Clinical Trial Results of a HER2/neu(E75) Vaccine to Prevent Recurrence in High Risk Breast Cancer Patients. J Clin Oncol 2005;23:7536-45.
• Woll MM, Fisher CM, Ryan GB, Gurney JM, Storrer CE, Ioannides CG, Shriver CD, Moul JW, McLeod DG, Ponniah S, and Peoples GE. Immunotherapy of Folate Receptor-Expressing Tumors: Review of Recent Advances and Future Prospects. (2003) Journal of Controlled Release, 91 (1-2) pp 17 -29.
• Gurney JM, Woll MM, Storrer CE, Fisher CM, Shriver CD, Ponniah S, and Peoples GE. In vivo monitoring of the immune response in breast cancer patients receiving a HER2/neu peptide vaccine. J Am Coll Surg 2003;187(suppl):S81-82.
• Peoples GE, Anderson BW, Lee TV, Murray JL, Kudelka, AP, Wharton, JT and Ioannides, CG. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999;5:1289-97.
• Anderson B, Lu JJ, Ibrahim N, Hortobagyi G, Brewer H, Przepiorka D, Ioannides C, Grabstein K, Cheever M, and Murray J.  Ovarian cancer-associated lymphocyte recognition of folate binding protein (FBP) peptides. Ann Surg Oncol 1998;5:743-50.
• Zaks TZ and Rosenberg SA. Ovarian Cancer-Associated Lymphocyte Recognition of Folate Binding Protein Peptides. Annals of Surgical Oncology 1998, 5(8):743 – 750.